Glenmark initiates multi-nation Phase 3 clinical trial for lung cancer drug

Glenmark Pharmaceuticals has commenced a Phase 3 clinical trial across multiple countries, including India, Russia, Brazil, and Mexico, for Envafolimab, a novel drug targeting third-stage non-small cell lung cancer (NSCLC). The trial aims to evaluate the drug's efficacy, safety, and other key parameters in NSCLC patients.